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Objective: To increase the power of nasal potential difference (NPD) as a biomarker of CFTR function, improvement of its repeatability is needed.
We evaluated the improvement in repeatability resulting from measuring NPD (1) over a larger surface area and (2) at a ﬁxed location.
Methods: To assess repeatability, NPD was measured on two occasions with a new method using a larger surface catheter at ﬁxed locations on the
nasal ﬂoor (LSC-ﬂoor5cm and LSC-ﬂoor3cm) or at the most negative basal potential (LSC-ﬂoormax); with a sidehole catheter on the nasal ﬂoor at
5 cm from the nasal margin (SHC-ﬂoor5 cm) or at the most negative potential (SHC-ﬂoormax); and with an endhole catheter below the inferior
surface of the lower turbinate at the most negative potential (EHC-turbmax).
Results: The within-subject standard deviation (Sw) for repeated measurements of the total chloride response in the controls was smallest with the
LSC-ﬂoor at a ﬁxed location (LSC-ﬂoor5 cm 3.1 mV; 95% CI 2.3–4.6 mV) and highest with the SHC-ﬂoor (SHC-ﬂoormax 14.6 mV; 95% CI
10.9–22.2 mV) or the EHC-turbinate (EHC-turbmax 12.5 mV; 95% CI 10.7–23.0 mV) at the most negative basal potential. Measuring with the
LSC-ﬂoor at the maximal potential increased the Sw (LSC-ﬂoormax 8.8 mV, 95% CI 6.0–16.1 mV, p = 0.009 vs LSC-ﬂoor5 cm), while measuring
with the SHC-ﬂoor at a ﬁxed location slightly decreased the Sw (SHC-ﬂoor5 cm 9.8 mV, 95% CI 8.9–20.6 mV, p = 0.06 vs SHC-ﬂoormax). In
patients with cystic ﬁbrosis, the Sw was comparable, between 2.2 mV and 4.3 mV. Sample size calculations for trials using NPD to assess changes
in ion transport showed that the number of subjects to be included could be approximately halved measuring with the larger surface catheter at a
ﬁxed location vs SHC or EHC at ﬁxed locations.
Conclusion: Measuring the NPD at a ﬁxed location and over a larger surface resulted in increased repeatability and thereby also power as a
biomarker of CFTR modulation.
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In patients with cystic fibrosis (CF), defective chloride
transport through the cystic fibrosis transmembrane conductance
regulator (CFTR) is the initiator of a pathophysiological cascade
leading to respiratory disease. The first therapy targeting the basic
CF ion transport defect was recently licensed. Ivacaftor improves
chloride transport [1] and also improves lung function, increases
weight and decreases the exacerbation rate in patients harboring
the G551D mutation [2]. Therapies targeting the CFTR defect in
patients with other CF mutations are under development.
Lumacaftor aims to increase the amount of CFTR protein at thell rights reserved.
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read-through of premature nonsense mutations [4].
These therapies are examples of personalized medicine
because they are geared towards patients with a specific mutation
class. While phase 3 efficacy trials with CFTR modulators are
feasible for frequent CFTR mutations, such trials will be more
challenging for rare mutations.
Therefore, biomarkers that predict the effects of these new
therapies in patients with rare mutations are needed [5]. The
nasal potential difference (NPD) directly measures the ion
transport in the airways and is consistently abnormal in patients
with CF [6]. In early studies, aminoglycosides [7] and ataluren
[8] have been shown to improve chloride transport in patients
with nonsense mutations. Treatment with ivacaftor partially
corrects the chloride and sodium transport defects observed on
NPD in G551D patients [1].
However, NPD measurements are highly variable [9–11],
leading to decreased power to detect changes with treatment [12].
To improve the repeatability of the measurements, standard
operating procedures (SOPs) were devised [13,14], the central
reading of tracings during clinical trials was instituted [1], and the
processing of the obtained values was optimized [15]. Despite
these measures, the NPD measurement variability remains high.
The goal of the present study was to compare a new method of
measuring the NPD with previously described measurement
methods, with regard to repeatability. Two major changes were
introduced in the measurement technique. First, the measurement
surface area was increased to average the potentials from a larger
area of the epithelium. Second, the repeat measurements were
performed at a fixed location instead of at the spot of the most
negative basal potential. Our hypothesis was that these technical
modifications would increase the repeatability of the NPD
measurement and thus the power to detect therapeutic effects.
2. Methods
2.1. Subjects
Patients with CF were recruited during outpatient clinic
visits or during admission. The control subjects were recruited
through an advertisement. All of the subjects had to be free of
any acute upper airway symptoms for more than two weeks.
Smokers were excluded. The ethics committee of the Univer-
sity of Leuven approved the study. Caregivers and/or the
participants gave written informed consent. Subjects could
contribute to the evaluation of more than one measurement
method, but not all methods were evaluated in each subject.
2.2. Nasal potential difference
The NPD was measured between an intranasal agar-filled
catheter and an agar-filled subcutaneous needle (21G or 23G).
Potentials were recorded with calomel electrodes (Calomel
Reference Electrode, Radiometer Analytical, Villeurbanne,
France) connected through a head stage to a bio-amplifier
(ISO-Z Isolated Head-Stage and BMA-200 AC/DC Portable
Preamplifier, AD Instruments, New Zealand) and a digitalrecorder (Powerlab 4/30, AD Instruments, New Zealand), as
described in both of the available SOPs [13,14].
The potential was measured sequentially during perfusion
at 5 ml/min with Ringer's solution, Ringer's solution with
100 μM amiloride, a zero-chloride solution with 100 μM
amiloride and a zero-chloride solution with 100 μM amiloride
and 10 μM isoprenalin. Each solution was perfused for 3 min
or until a stable potential value was obtained, whichever was
longer. Solutions were not warmed, as only a minor effect is
expected on the potential measurements [16].
Three main indices were calculated: (1) the total chloride
response (TCR) was the sum of the change in the NPD
observed after changing from the amiloride in Ringer's solution
to the amiloride in zero-chloride solution plus the change after
changing to the isoprenalin plus amiloride in zero-chloride
solution; (2) the Ringer's PD was the NPD at the end of the
perfusion with Ringer's solution; and (3) the delta NPD was the
change in the NPD from the end of the perfusion with Ringer's
solution to the end of the perfusion with the isoprenalin plus
amiloride in zero-chloride solution.
Tracings with both the amiloride response lower than 5 mV
and the TCR higher than −5 mV were considered ‘flat tracings’
and were not used for further analysis.
The following different methods were compared (Table 1).
1. The new ‘larger surface catheter’ method (LSC-floor5 cm):
the NPD was measured with a larger surface agar-coated
electrode (agar coating of 2 cm length over 360° with a
diameter of 4.5 mm, Fig. 1 and Fig. S1 in the online
supplement) secured with the tip 5 cm past the nasal margin.
2. SHC-floormax: the NPD was measured along the nasal floor
with an 8 Fr single lumen side-hole nasogastric catheter
(Fig. 1). The solutions were perfused through polyethylene
PE90 tubing ending near the opening of the measuring
electrode, attached by a short silicone sheat. The catheter
was secured at the site of the most negative basal potential.
This measurement method is close but not identical to the
ECFS-CTN SOP [13], which advocates the use of a sidehole
Marquat catheter while a home-made sidehole catheter was
used in the present study.
3. EHC-turbmax: the NPDwasmeasured at the lower surface of the
inferior turbinate with an end-hole 2.5-mm catheter (Marquat
Genie Biomedical, Boissy-Saint-Léger, France, Fig. 1). Perfu-
sion of the solutions was achieved through the second lumen of
the catheter. The catheter was inserted under visualization with
a nasal speculum and a headlamp and was secured when the
location with the most negative basal potential was identified.
This method is similar to the one used for the ataluren trial [8]
and differs from the actual CFF-TDN SOP in two ways: the
solutions were not warmed and aMarquat endhole catheter was
used instead of a PE90/PE50 home-made catheter.
4. Additional methods were tested to assess the respective
contributions of the two modifications — larger surface and
fixed location — to the improvement in repeatability:
◦ SHC-floor5 cm: the sidehole catheter was tested with
the catheter secured at a fixed location on the nasal
Table 1
Comparison between the Ringer's PD values and the total chloride response measured with different methods in control subjects and patients with cystic fibrosis.
Method LSC-floor5 cm SHC-floormax EHC-turb max SHC-floor5 cm LSC-floor3 cm LSC-floormax
Catheter type
Location
Larger surface
Nasal floor
5 cm
Side-hole
Nasal floor
Most neg PD
End-hole
Inferior turbinate
Most neg PD
Side-hole
Nasal floor
5 cm
Larger surface
Nasal floor
3 cm
Larger surface
Nasal floor
Most neg PD
No. flat tracings/total no. of tracings 2/54 7/60 1/46 6/34 14/100 0/20
Total chloride
response (mV)
Controls No. of valid tracings 36 35 27 12 67 20 ⁎⁎
Mean −22.9 −24.2 −36.6 ⁎⁎⁎⁎ −40.1 ⁎⁎⁎ −13.3 ⁎ -15.2
SD 9.0 15.2 13.8 12.5 7.3 7.7
Mean difference d2-d1 −1.2 −4.7 0.1 3.8 −1.2 −4.2
SD difference d2-d1 4.4 20.8 18.3 15.0 6.3 12.4
Within-subject SD 3.1 14.6 ⁎⁎⁎⁎ 12.5 ⁎⁎⁎⁎ 9.8 ⁎⁎⁎⁎ 4.5 8.8 ⁎⁎⁎⁎
CF No. of valid tracings 16 18 18 16 19
Mean 0.8 1.4 −2.8 1.4 2.3
SD 5.6 3.7 4.6 8.7 2.3
Mean difference d2-d1 0.9 −2.6 −2.0 0.5 −1.7
SD difference d2-d1 5.3 3.8 6.0 6.4 2.9
Within-subject SD 3.3 3.1 4.3 4.2 2.2
Ringer's PD (mV) Controls No. of valid tracings 36 35 27 12 67 20
Mean −11.9 −14.6 −22.5 ⁎⁎⁎⁎ −10.5 −10.0 −13.3
SD 6.1 7.2 11.2 4.8 3.8 4.3
Mean difference d2-d1 −1.5 −1.1 0.3 0.8 0.4 −0.3
SD difference d2-d1 4.5 4.7 4.9 6.0 2.0 5.0
Within-subject SD 3.0 3.3 3.4 3.8 1.4 3.4
CF No. of valid tracings 16 18 18 16 19
Mean −48.2 −40.6 −58.9 −55.1 −29.2
SD 16.8 13.7 11.8 12.7 9.1
Mean difference d2-d1 4.4 11.6 −0.9 2.6 3.2
SD difference d2-d1 9.3 14.2 14.8 17.1 5.8
Within-subject SD 6.9 12.5 9.9 11.4 4.5
CF: cystic fibrosis; EHC: endhole catheter; LSC: larger surface catheter; neg PD: negative potential difference; SHC: sidehole catheter; turb: inferior surface of the
inferior turbinate; TCR: total chloride response. Only the differences between each method and the new LSC-floor5 cm method were assessed.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p = 0.001.
⁎⁎⁎⁎ p b 0.001 compared with the new method.
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method.
◦ LSC-floor3 cm: the new larger surface catheter was used
with the tip secured 3 cm past the nasal margin.
◦ LSC-floormax: the new larger surface catheter was used with
the catheter secured at the site of the most negative basal
potential, similarly to the SHC-floormax and EHC-turbmax
methods.
In each subject, both nostrils were measured simultaneously
using a different technique. For the EHC-turbmax only one
nostril was tested because testing the other nostril at the same
time with another technique would have compromised the
precise location of the catheter.
2.3. Statistics
To estimate the repeatability, the mean difference plus the
standard deviations of the difference and a Pearson's correla-
tion between the repeated measurements were calculated. Bland
and Altman plots with 95% limits of agreement were computed.In addition, a one-way ANOVA using subject as factor was used
to estimate the within-subject standard deviation [17], separately
for each method as not all methods were evaluated in each
subject. The variances were compared using Levene's test.
Fischer's exact test was used to compare the proportion of flat
tracings between the methods. The mean values obtained with
each method were compared using ANOVA and post-hoc
Scheffé testing. Power calculations were carried out based on
the means and standard deviations (SDs) of the differences
between the measurements of the control subjects and the patients
with CF. The power was calculated for the treatment effects
predicted to correct the PDs by 10, 20 and 30% towards the values
in the control subjects for a 1-sample t-test with a significance
level of 0.05 and a power of 0.90.3. Results
The nasal potential difference was measured in 113 subjects
(76 controls and 37 patients with CF). The median number of
methods tested in each subject was 2 (range 1–5). After a
Fig. 1. Catheters used for the nasal potential difference measurements: (A) an
8 Fr side-hole catheter used for the SHC-floor method; (B) a larger surface
catheter used for the new LSC-floor method; and (C) a Marquat catheter used
for the EHC-turb method. EHC: endhole catheter; LSC: larger surface catheter;
SHC: sidehole catheter; turb: inferior surface of the inferior turbinate.
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repeated using the same method in the same nostril.
3.1. Repeatability
The means and SDs of the differences between the repeated
measurements and the within-subject standard deviations are
given in Table 1. There were no systematic differences between
the repeated measurements of the TCR or the Ringer's PD for
all of the techniques (Table 1 and Fig. 2). For the TCR in the
controls, the within-subject SD was smaller when the potential
was measured with the new method (LSC-floor5 cm 3.1 mV,
95% CI 2.3–4.6 mV) than with the SHC-floormax method
(14.6 mV, 95% CI 10.9–22.2 mV, p b 0.001) or with the
EHC-turbmax method (12.5 mV, 95% CI 10.7–23.0 mV,
p b 0.001). Measuring with the larger surface catheter at the
location of the most negative potential instead of at a fixedFig. 2. Bland and Altman plots comparing the TCR measured on day 1 (d1) and day
diamonds) and in patients with CF (red triangles). The solid lines are the mean dif
subjects (blue) and patients with CF (red). CF: cystic fibrosis; EHC: endhole cathete
the inferior turbinate; TCR: total chloride response.location resulted in a higher within-subject SD (LSC-floormax
8.8 mV, 95% CI 6.0–16.1 mV, p = 0.009), while measuring
with the side-hole catheter at a fixed location instead of at the
site of the most negative basal PD also reduced the within-
subject standard deviation (SHC-floor5 cm 9.8 mV, 95% CI
8.9–20.6 mV, p = 0.06).
In the patients with CF, the within-subject SDs for the TCR
were similar between the different techniques (from 2.2 to
4.3 mV).
The correlation between the repeated measurements of the
TCR (Fig. 3) was 0.95 (95% CI 0.91–0.98) with the new
LSC-floor5 cm method, 0.57 (95% CI 0.22–0.77) with the
SHC-floormax method and 0.76 (95% CI 0.58–0.90) with the
EHC-turbmax method.
The results for the Ringer's PD and delta NPD are shown in
Table 1, Table S1 and Figures S2 to S6.3.2. Flat tracings
The number of flat tracings obtained with each method is
given in Table 1. There were more flat tracings using a
side-hole catheter on the nasal floor than using an end-hole
catheter under the inferior turbinate (13/94 vs. 1/46, p = 0.035).
At 5 cm from the nasal margin, the use of a larger surface
catheter resulted in marginally less frequent flat tracings
compared with the use of a side-hole catheter (2/54 vs. 6/34,
p = 0.05).3.3. Discriminative power between patients with CF and
controls
All of the measurement techniques differentiated well between
the control subjects and the patients with CF (Fig. 4), with some
overlap for the TCR and the Ringer's PD. As a combined index
reflecting the sodium and chloride transport, the delta NPD was
even more discriminative (Figure S2).2 (d2) in the same nostril with the same technique in the control subjects (blue
ferences, and the dashed lines are the 95% limits of agreement for the control
r; LSC: larger surface catheter; SHC: sidehole catheter; turb: inferior surface of
Fig. 3. Correlation between the TCR measured on day 1 (d1) and day 2 (d2) in the same nostril with the same technique in the control subjects (blue diamonds) and
CF patients (red triangles). The solid line is the line of equality. CF: cystic fibrosis; EHC: endhole catheter; LSC: larger surface catheter; SHC: sidehole catheter; turb:
inferior surface of the inferior turbinate; TCR: total chloride response.
A
B
Fig. 4. TCR (A) and Ringer's PD (B) measured in individual nostrils using the
different methods in the control subjects (blue diamonds) and in patients with
cystic fibrosis (red triangles). CF: cystic fibrosis; EHC: endhole catheter; LSC:
larger surface catheter; SHC: sidehole catheter; turb: inferior surface of the
inferior turbinate; TCR: total chloride response.
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The mean values for the Ringer's PD and the TCR for each
technique are given in Table 1. The individual values for the
control subjects and the patients with CF are shown in Fig. 4.
In the controls, the mean TCR was significantly higher with
the EHC-turbmax method (−36.6 ± 13.8 mV) or when mea-
sured with the side-hole catheter on the nasal floor at 5 cm deep
(−40.1 ± 12.5 mV) than on the nasal floor with the larger
surface catheter (−13.3 ± 7.3 mV at 3 cm deep, p = 0.002, and
−22.9 ± 9.0 mV at 5 cm deep, p b 0.001). Using the larger
surface catheter, the measurements at a fixed depth of 5 cm (new
method) resulted in a higher TCR than at 3 cm (−22.9 ± 9.0 mV
vs. −13.3 ± 7.3 mV, p = 0.003). In the patients with CF, there
was no significant difference in the TCR between the different
measurement techniques.
3.5. Power calculations
The sample sizes were estimated assuming a 1-sample t-test
for the difference between the baseline and follow-up measure-
ments. Different levels of improvement of the parameters were
hypothesized based on the range of values observed in the ivacaftor
trial [15]. The results are reported in Table 2, showing lower
sample sizes for most parameters with the new LSC-floor5 cm
method compared with the SHC-floormax and EHC-turbmax
methods, but similar sample sizes when the TCR was measured
with the sidehole catheter at 5 cm depth on the nasal floor or with
the new method.
4. Discussion
Compared with previous methods, the repeatability of the
NPD measurement was much improved by using a larger
surface catheter placed at a fixed location. This improvement in
the repeatability increased the power of the NPD measurement
as a biomarker to detect changes in CFTR activity.
Different hypotheses could explain the improvement in the
repeatability. First, using a fixed location for the measurement
Table 2
Sample size calculations.
Improvement (towards values in controls) LSC-floor5 cm SHC-floormax EHC-turb max SHC-floor5 cm LSC-floor3 cm
Total chloride response 10% 51 49 49 33 46
20% 13 21 17 11 14
30% 6 15 10 5 8
Ringer's PD 10% 63 273 152 136 84
20% 14 59 33 30 19
30% 6 23 13 12 7
Delta NPD 10% 35 63 43 39 46
20% 8 19 11 10 12
30% 4 10 6 5 6
CF: cystic fibrosis; EHC: endhole catheter; LSC: larger surface catheter; neg PD: negative potential difference; SHC: sidehole catheter; turb: inferior surface of the
inferior turbinate.
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measurement. Ion transport is not uniform throughout the nasal
cavity. According to early work from Knowles et al. [18],
measurements were initially taken from the inferior surface of
the lower turbinate because the basal PD was the most negative
and the mucosal histology showed the highest proportion of
ciliated cells. However, the insertion of the catheter under the
lower turbinate was considered technically difficult by others,
leading to alternative protocols measuring the nasal floor [19].
Similar results were obtained when both methods were
compared [11]. Measuring at different locations instead of a
fixed area on different testing occasions may logically lead to
more variable results. In the present study, the repeatability was
indeed slightly worse when the measurement was taken from
the location of the most negative basal value than from a fixed
location, both with a side-hole catheter and with the larger
surface catheter. In addition, the usefulness of searching for an
‘optimal’ location is questionable because the TCR in the
controls was larger when using a fixed location rather than the
location with the most negative basal potential.
Second, measuring a larger surface area results in an
averaged value that is more likely to be repeatable in a
subsequent measurement.
Third, the properties of the catheters could have played an
important role. The larger surface catheter has a larger diameter
than side-hole or Marquat catheters, preventing its displace-
ment during measurement. With smaller catheters, the contact
with the nasal mucosa could be less consistent, and minor
differences in the orientation of the opening could impact the
measured values.
Before the nasal potential difference can be used as a
biomarker, this technique requires rigorous standardization.
However, even with standardization, small differences in
practice can have a major impact on the results obtained [20].
NPD values may vary considerably between operators accord-
ing to factors that are difficult to standardize such as the exact
location of the catheter, the care taken not to injure the mucosa
during catheter insertion, or stabilization of the catheter during
measurement. A ‘real life’ evaluation of the feasibility of NPD
measurement and its accuracy and reliability in the hands of
less-experienced operators should prove that the proposed
technique is appropriate for generalization. The use of a larger
surface catheter placed at a fixed location appears to be simplerthan using a small catheter, which is prone to displacement, under
the turbinate, a location that is more difficult to reach. In addition,
the use of a larger, firmly secured catheter allows simultaneous
measurements in both nostrils, halving the measurement time.
The amplitude of the TCR was higher when measured with a
small catheter than with the larger surface catheter. This result
is understandable because the latter averages the potentials over
a larger surface area, precluding the recording of a ‘peak’ value,
which would be the case with a small catheter. It is important to
note that the high values we measured using the EHCturb
method have not universally been found by others. A TCR of
only −25 mV was observed in control subjects in a multicenter
trial using a similar protocol [21], close to the value we found
with the larger surface catheter. The high values we obtained
could be due to subject characteristics (mainly young subjects
in our cohort) or residual methodological differences.
The repeatability of each method will be further increased by
averaging the values measured in each nostril [19]. Obtaining
more repeatable results from each side could allow to evaluate
other approaches than averaging both sides, such as using the
most polarized nostril [15].
The strengths of the present study were the large number of
measurements. A single experienced operator performed all of
the measurements, thereby avoiding the inter-operator variabil-
ity inherent to comparisons between different operators using
different techniques. The repeatability obtained with the SHC-
floormax and EHC-turbmax methods was similar to previously
published values [15,22]. The major weakness was that different
subjects were included in the evaluation of the different
techniques. From previous studies, we knew that repetition of
the nasal potential measurements was likely to lead to a high
dropout rate, especially in the control subjects. Another possible
hurdle in the implementation of the new method is the use of a
‘home made’ catheter, which could rise regulatory issues, as has
been the case for the ‘Marquat’ catheter in the Unites States.
Before further evaluation of a new method is started, designing a
catheter that will obtain approval by regulatory issues is an
important step. An alternative could be to assess the repeatability
using the actual SOPs and catheters, but taking the measurement
from a fixed location, and not the location with the most negative
basal potential.
We concluded that measuring the NPD both with a larger
surface catheter or at a fixed location, improved the repeatability
323F. Vermeulen et al. / Journal of Cystic Fibrosis 14 (2015) 317–323of the measurement, thereby reducing the sample size needed in
clinical trials. Future research should include multi-center
evaluations of these methodological adaptations to demonstrate
the superior power to detect therapeutic effects in patients with
CF.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.08.006.References
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